A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks and optionally for additional up to 3.5 years in women with, or at high risk for developing hormone-receptor positive breast cancer

Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

Mean change in frequency of moderate to severe hot flash (HF) from baseline to Week 4 (assessed by hot flash daily diary [HFDD])., Mean change in frequency of moderate to severe HF from baseline to Week 12 (assessed by HFDD).

Mean change in severity of moderate to severe HF from baseline to Week 4 (assessed by HFDD)., Mean change in severity of moderate to severe HF from baseline to Week 12 (assessed by HFDD)., Mean change in frequency of moderate to severe HF from baseline to Week 1 (assessed by HFDD)., Mean change in frequency of moderate to severe HF from baseline over time., Mean change in patient-reported outcomes measurement information system sleep disturbance short form 8b (PROMIS SD SF 8b) total score from baseline to Week 12., Mean change in menopause specific quality of life scale (MENQOL) total score from baseline to Week 12.

No related papers found yet.

Austria, Belgium, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Spain